CN118414328A - Ep4拮抗剂的结晶盐形式 - Google Patents

Ep4拮抗剂的结晶盐形式 Download PDF

Info

Publication number
CN118414328A
CN118414328A CN202280084209.3A CN202280084209A CN118414328A CN 118414328 A CN118414328 A CN 118414328A CN 202280084209 A CN202280084209 A CN 202280084209A CN 118414328 A CN118414328 A CN 118414328A
Authority
CN
China
Prior art keywords
compound
cancer
free acid
crystalline free
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280084209.3A
Other languages
English (en)
Chinese (zh)
Inventor
F·贝纳尤德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN118414328A publication Critical patent/CN118414328A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280084209.3A 2021-12-23 2022-12-22 Ep4拮抗剂的结晶盐形式 Pending CN118414328A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293183P 2021-12-23 2021-12-23
US63/293,183 2021-12-23
PCT/US2022/053842 WO2023122289A1 (en) 2021-12-23 2022-12-22 Crystalline salt form of ep4 antagonist

Publications (1)

Publication Number Publication Date
CN118414328A true CN118414328A (zh) 2024-07-30

Family

ID=85222399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280084209.3A Pending CN118414328A (zh) 2021-12-23 2022-12-22 Ep4拮抗剂的结晶盐形式

Country Status (7)

Country Link
US (1) US20250051285A1 (enExample)
EP (1) EP4452949A1 (enExample)
JP (1) JP2024545695A (enExample)
KR (1) KR20240124927A (enExample)
CN (1) CN118414328A (enExample)
CA (1) CA3242277A1 (enExample)
WO (1) WO2023122289A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
JP2024545695A (ja) 2024-12-10
CA3242277A1 (en) 2023-06-29
WO2023122289A1 (en) 2023-06-29
US20250051285A1 (en) 2025-02-13
KR20240124927A (ko) 2024-08-19
EP4452949A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US10710987B2 (en) Hydrochloride salt form for EZH2 inhibition
US12152034B2 (en) FGFR inhibitors and methods of making and using the same
AU2009220856B2 (en) Crystal form of phenylamino pyrimidine derivative
JP6414831B2 (ja) 繊維症の小分子阻害剤
CN101970425A (zh) 4-氨基-5-氟-3-[5-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]喹啉-2(1h)-酮乳酸盐的结晶形式和两种溶剂化形式
EP4469054A1 (en) Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
US20250051285A1 (en) Crystalline salt form of ep4 antagonist
CN104557870B (zh) 一种吡啶胺化合物的富马酸盐
US20240182443A1 (en) Polymorphic forms of compound and preparation method therefor and application thereof
JP6463874B2 (ja) 医学的適用用の３−（１，２，４−トリアゾロ［４，３−ａ］ピリジン−３−イルエチニル）−４−メチル−Ｎ−（４−（（４−メチルピペラジン−１−イル）メチル）−３−トリフルオロメチルフェニル）ベンズアミドの新規な結晶性塩形態
CA3211477A1 (en) Salt and solid forms of a kinase inhibitor
JP2010527369A (ja) （（フェニル）イミダゾリル）メチルヘテロアリール化合物
EP4615845A1 (en) Salts and solid forms of a compound having apj receptor activity
CN117693517A (zh) 用于靶向治疗肾癌的新型化合物和组合物
RU2481335C2 (ru) Производные дигидроимидазола, замещенного конденсированным карбоциклом, используемые для снятия боли и лечения состояний, подобных глаукоме
JP7819298B2 (ja) Ｅｐ４拮抗剤化合物及びその塩、結晶多形並びに使用
HK40109783A (en) Hydrochloride salt form for ezh2 inhibition
WO2025139868A1 (zh) Trpv3抑制剂及其制备和应用
CN102336740B (zh) 一类咪唑类化合物及其用途
CN118459465A (zh) 氘代稠合杂环化合物及其制备方法和药物组合物、结合物及应用
NZ718201B2 (en) Hydrochloride salt form for ezh2 inhibition
WO2005092065A2 (en) Novel tricyclic compounds and related methods of treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination